论文部分内容阅读
目的观察替加色罗治疗慢性便秘、消化不良和反流症状重叠群的疗效。方法慢性便秘与消化不良和(或)反流症状重叠患者88例,随机分为三组,替加色罗(TEG)组服用替加色罗6 mg,每天2次,餐前30 min服用;质子泵抑制剂(PPI)组服用埃索美拉唑40 mg,每天1次,早餐前30 min服用;联合治疗组服用替加色罗及埃索美拉唑。疗程均为4周。疗效评价指标为:主要症状的完全缓解率及胃肠道症状总积分、胃肠动力和胃感觉改变。结果治疗4周后,三组胃肠道症状总积分均较治疗前明显下降(P<0.01)。其中TEG组(7.23±3.13)和联合治疗组(5.13±2.26)的总积分下降较PPI组(13.58±2.26明显.P<0.01)。4周治疗结束时,TEG组上腹痛/不适和烧心症状的完全缓解率分别为59.3%、40.0%,PPI组分别为32.1%、57(?)%,联合治疗组分别为74.1%、84.6%,其中TEG组上腹痛/不适的完全缓解率明显高于PPI组(59.3%比32.1%.P=0.043),而烧心症状的完全缓解率明显低于联合治疗组(40.0%比84.6%,P=0.016)。结论替加色罗治疗慢性便秘与消化不良和(或)反流症状重叠群具有良好的疗效和安全性。
Objective To observe the effect of tegaserod on chronic constipation, dyspepsia and reflux syndrome. Methods Eighty - eight patients with chronic constipation and overlapping dyspepsia and / or reflux symptoms were randomly divided into three groups. Tegaserod (TEG) group was treated with tegaserod 6 mg twice daily and 30 min before meal. The proton pump inhibitor (PPI) group received 40 mg esomeprazole once daily and 30 min before breakfast. The combination therapy group took tegaserod and esomeprazole. The course of treatment is 4 weeks. Efficacy indicators for the evaluation of the main symptoms of complete remission rate and total gastrointestinal symptoms, gastrointestinal motility and gastric sensory changes. Results After 4 weeks of treatment, the total scores of gastrointestinal symptoms in the three groups were significantly lower than those before treatment (P <0.01). The total score of TEG group (7.23 ± 3.13) and combination therapy group (5.13 ± 2.26) decreased more than that of PPI group (13.58 ± 2.26, P <0.01). At the end of the 4-week treatment, the complete remission rates of upper abdominal pain / discomfort and heartburn were 59.3% and 40.0% in the TEG group and 32.1% and 57%, respectively in the PPI group and 74.1% and 84.6% in the combined treatment group, respectively , The complete remission rate of upper abdominal pain / discomfort in TEG group was significantly higher than that in PPI group (59.3% vs 32.1%, P = 0.043), while the complete remission rate of heartburn symptom was significantly lower than that in combination therapy group (40.0% vs 84.6%, P = 0.016). Conclusion Tegaserod has a good curative effect and safety in treating chronic constipation and congenital dyspepsia and / or reflux symptoms.